Crispr Therapeutics AG (CRSP)

[jondoeuk]

CRSP continues to expect to move multiple programs utilising in vivo approaches into the clinic in the next 12 to 18 months, including programs in cardiovascular disease. The company’s lead program, CTX310, targeting angiopoietin-related protein 3 (ANGPTL3) is currently in IND-enabling studies. Also, CTX320 (LP(a)) and CTX330 (PCSK9) are at the research stage, but they could combine all three. In addition, they have established CRISPR-X, a dedicated group within that focuses on emerging technologies, including those to allow HDR-independent and/or AAV-free whole gene correction and insertion.